ACTRN12624000800527尚未招募Unknown
Acute effect of the renally excreted low-calorie sweetener, acesulfame potassium (Ace-K), on urinary glucose excretion in healthy humans.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 79 Years（—）
- 性别
- All
入选标准
- •Healthy males and females aged from 18 to 70 years
- •- Body mass index (BMI) from 18 to 30 kg/m2
- •- HbA1c less than 5.7%
- •- Fasting blood glucose less than 5.6 mmol/L
排除标准
- •- Habitual use of more than one serve of any food or beverage containing a low-calorie sweetener per day during the past 3 months, ascertained using a low-calorie sweetener frequency questionnaire.
- •- Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a daily basis
- •- Haemoglobin below the lower limit of the normal range (ie. < 135 g/L for men and 115 g/L for women), and ferritin below the lower limit of normal (ie. < 30 ng/mL for men and 20 mg/mL for women)
- •- Female participants who are pregnant or planning for pregnancy, or are lactating
- •- History of any form of heart disease or symptoms of syncope or pre-syncope (including feeling lightheaded or dizzy, feeling unsteady when standing, unexplained falls, fainting, unexplained changes in vision, such as blurring or tunnel vision)
- •- Other significant illness, including epilepsy, cardiovascular or respiratory disease
- •- Impaired renal or liver function (as assessed by calculated creatinine clearance less than 60 mL/min or abnormal liver function tests (more than 2 times upper limit of normal range))
- •- Donation of blood within the previous 3 months
- •- Participation in any other research studies within the previous 3 months
- •- Inability to give informed consent
- •- Vegetarians
研究者
相似试验
进行中（未招募）
不适用
Acute effect of the renally excreted low-calorie sweetener, acesulfame potassium (Ace-K), on urinary glucose excretion in people with type 2 diabetes.Type 2 diabetesMetabolic and Endocrine - DiabetesACTRN12623000094673The University of Adelaide17
已完成
Unknown
The Effects of dapagliflozin in patients with type 2 Diabetes in a rural hospital in South IndiaCTRI/2023/04/051669THE SCHIEFFELIN INSTITUTE OF HEALTH-RESEARCH AND LEPROSY CENTER
进行中（未招募）
1 期
Study of the effects of sodium-glucose cotransporter 2 inhibitors on kidney function and metabolism in patients that undergo cardiac surgery.Cardiac surgery-associated acute kidney injuryMedDRA version: 20.1Level: LLTClassification code 10080266Term: Stage 1 acute kidney injurySystem Organ Class: 100000004857EUCTR2021-003172-13-NLAmsterdam UMC80
招募中
不适用
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosisJPRN-UMIN000040179Hokkaido University400
进行中（未招募）
1 期
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851EUCTR2014-005033-31-FRAddmedica S.A.S